Dr. Dario Vignali is the Frank Dixon Chair in Cancer Immunology and Vice Chair and Professor of Immunology at University of Pittsburgh School of Medicine.  His lab studies various aspects of T cell regulation, and recently generated a new mouse model to target conventional CD4 T cells.
Read More
Dr. Jeffrey Bluestone is the CEO and President of Sonoma Biotherapeutics, a San Francisco and Seattle-based company leveraging the properties of regulatory T cells to create living cell therapies that restore the immune system back to its balanced, fully functioning state.
Read More
Dr. Christopher Klebanoff is an Principal Investigator and Attending Physician at the Memorial Sloan Kettering Cancer Center. His research focuses on cell-based cancer immunotherapies, T cell receptors, and the therapeutic targeting of shared cancer neoantigens. Using single-cell sequencing, biophysical measurements of T cell receptor affinity, genetic engineering, and structural immunobiology, the Klebanoff lab aims to adapt adoptive T cell transfer for advanced solid tumors.
Read More
Dr. Marc Jenkins is a Regents and Distinguished McKnight University Professor in the Department of Microbiology and Immunology and the Director of the Center for Immunology at the University of Minnesota. Dr. Jenkins discovered that CD4+ T cells require CD28 as well as TCR to produce IL-2. The Jenkins lab is focused on the basic biology of CD4+ T lymphocytes.
Read More